Information  X 
Enter a valid email address

Hikma Pharmaceuticals annual profit rises on injectables sales growth

By BFN News | 08:16 AM | Thursday 25 February, 2021


Pharmaceutical company Hikma Pharmaceuticals reported a rise in profit led by growth in its injectables business. For the year ended 31 December 2020, pre-tax profit rose to $558 million from $491 million last year and revenue to rise 6% to $2.34 billion. Injectables revenue was increased by 9% to $977 million, while generics revenue was up 3% and branded up 5% to £613 million. Looking to 2021, injectables revenue growth was forecast to grow in the mid-single digits, with core operating margin in the range of 37% to 38%; generics revenue in the range of $770 million to $810 million and branded revenue expected to grow in the mid-single digits in constant currency. At 8:16am: (LON:HIK) Hikma Pharmaceuticals PLC share price was 0p at 2659p Story provided by StockMarketWire.com

a d v e r t i s e m e n t